Elanco Animal Health Inc (ELAN) FinancialsELANElanco Animal Health Inc

Elanco Animal Health Incorporated (ELAN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Pet Health, accounting for 52.5% of total sales, equivalent to $718.00M. Other significant revenue streams include Farm Animal and Contract Manufacturing. Understanding this composition is critical for investors evaluating how ELAN navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Elanco Animal Health Incorporated maintains a gross margin of 48.17%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 8.63%, while the net margin is 3.95%. These profitability ratios, combined with a Return on Equity (ROE) of -2.98%, provide a clear picture of how effectively ELAN converts its operational activities into shareholder value.

In the context of the broader market, ELAN competes directly with industry leaders such as ARWR and HALO. With a market capitalization of $12.05B, it holds a significant position in the sector. When comparing efficiency, ELAN's gross margin of 48.17% stands against ARWR's 100.00% and HALO's 77.40%. Such benchmarking helps identify whether Elanco Animal Health Incorporated is trading at a premium or discount relative to its financial performance.

Elanco's revenue for Q2 2026 was 1.368 billion USD, reflecting a solid growth trajectory. The gross margin has improved significantly, reaching 48.17%, which indicates efficient cost management and pricing power.